文献速递乳房整形与再造

AlloDerm、SurgiMend与Dermacell在胸肌前假体乳房再造中的手术与患者报告结局无差异

No Differences in Surgical and Patient-Reported Outcomes among AlloDerm, SurgiMend, and Dermacell for Prepectoral Implant-Based Breast Reconstruction.
PubMed 文献 · Plast Reconstr Surg · 2022-12-19

该回顾性研究纳入2018年1月至2019年12月接受即刻胸肌前假体乳房再造的连续患者,比较AlloDerm、SurgiMend与Dermacell三种脱细胞真皮基质的总并发症与BREAST-Q患者报告结局。结果显示三种ADM总并发症率及患者报告结局均无显著差异。

要点

  • AlloDerm、SurgiMend与Dermacell三组总并发症率分别为27%、33%、39%,差异无统计学意义(P=0.209)。
  • 多变量脆弱模型显示ADM类型与总并发症、感染、重大并发症或假体取出无显著关联。
  • 三种ADM的BREAST-Q乳房满意度、心理社会幸福感及性幸福感均相似。

核心结论

  • 在美国常用的三种ADM用于胸肌前假体乳房再造时,手术结局与患者报告结局相似。
  • AlloDerm、SurgiMend与Dermacell在感染、总并发症或假体取出率方面未发现显著差异。

研究设计与样本

  • 回顾性综述,纳入2018年1月至2019年12月接受即刻胸肌前假体乳房再造的连续患者。
  • 共纳入557个乳房(383例患者),AlloDerm占78.6%,SurgiMend占14%,Dermacell占7.4%。
  • 比较三种ADM的手术结局与BREAST-Q患者报告结局。

主要发现

  • Dermacell组患者较AlloDerm与SurgiMend组年龄更大(P=0.001),且更可能患有糖尿病(P=0.001)。
  • 三组总并发症率分别为AlloDerm 27%、SurgiMend 33%、Dermacell 39%,差异无统计学意义(P=0.209)。
  • 多变量脆弱模型显示ADM类型与总并发症、感染、重大并发症或假体取出无显著关联。
  • BREAST-Q乳房满意度、心理社会幸福感及性幸福感在三组间相似(分别为P=0.109、P=0.439、P=0.152)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prepectoral implant-based breast reconstruction (IBR) has become the standard of care for many reconstructive surgeons and is often supplemented with coverage using acellular dermal matrix (ADM). However, more clinical data examining the use of ADM in breast reconstruction are needed. The current study compares complications and patient-reported outcomes (PROs) among three different types of ADM used in IBR. METHODS: The authors performed a retrospective review of consecutive patients who underwent immediate prepectoral IBR from January of 2018 through December of 2019. Surgical outcomes and PROs (using the BREAST-Q) were compared among the AlloDerm, SurgiMend, and Dermacell ADMs. RESULTS: Overall, 557 breasts (383 patients) were included (78.6% AlloDerm, 14% SurgiMend, 7.4% Dermacell). Patients in the Dermacell group were older ( P = 0.001) and more likely to have diabetes ( P = 0.001) compared with AlloDerm and SurgiMend patients. Other patient characteristics were similar among the three groups. The overall complication rate was equivalent among the three ADM groups (AlloDerm 27% vs SurgiMend 33% vs Dermacell 39%; P = 0.209). Multivariable frailty models demonstrated that the type of ADM was not significantly associated with overall complications, infection, major complications, or device explantation. BREAST-Q satisfaction with breasts, psychosocial well-being, and sexual well-being were also similar among the three ADM groups ( P = 0.109, P = 0.439, P = 0.152, respectively). CONCLUSIONS: Three of the most commonly used ADMs in the United States have similar surgical outcomes and PROs when used for prepectoral IBR. No significant differences in infection, overall complications, or device removal rates were identified among AlloDerm, SurgiMend, and Dermacell. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Asaad M, Morris N, Selber JC, et al. No Differences in Surgical and Patient-Reported Outcomes among AlloDerm, SurgiMend, and Dermacell for Prepectoral Implant-Based Breast Reconstruction. Plast Reconstr Surg. 2022. PMID: 36525574. doi:10.1097/PRS.0000000000010070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。